Ingersoll Rand to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ingersoll Rand (NYSE: IR) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 7:30 a.m. Pacific Time. Senior management attending includes chairman & CEO Vicente Reynal, CFO Vik Kini, and Scott Watson, SVP and GM, Life Science Technologies.
A real-time audio webcast of the fireside chat will be available via the Events and Presentations section of the Ingersoll Rand Investor Relations website, and a replay will be posted after the presentation.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed, mostly modest moves, with names like XYL and ROK up while OTIS and SYM are slightly down. No broad sector momentum flagged, suggesting IR’s setup is more stock-specific ahead of the healthcare conference.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Board appointment | Positive | -1.9% | Added experienced director Jerome Guillen to support strategic initiatives. |
| Nov 03 | Bolt-on acquisition | Positive | +1.6% | Acquired Transvac to expand ejector technology and sustainability solutions. |
| Oct 23 | Dividend declaration | Neutral | -0.7% | Declared regular quarterly cash dividend of $0.02 per share. |
| Oct 10 | Earnings schedule | Neutral | +0.0% | Announced timing for Q3 2025 earnings release and conference call. |
| Aug 21 | Investor conference | Neutral | -2.0% | Outlined participation in Morgan Stanley Laguna investor conference. |
Recent news shows mixed price reactions: a positive acquisition drew gains, while board expansion and conference participation saw modest declines, indicating investors do not consistently reward corporate or IR-event updates.
Over the last few months, Ingersoll Rand has reported several corporate and investor‑focused developments. On Aug 21, 2025, it highlighted participation in an investor conference, followed by scheduling its Q3 2025 earnings call on Oct 10, 2025. A regular dividend declaration on Oct 23, 2025 and the Transvac acquisition on Nov 3, 2025 showed capital return and bolt‑on M&A activity. The Board expansion with Jerome Guillen on Dec 17, 2025 added governance depth. Today’s J.P. Morgan Healthcare appearance continues this pattern of active investor engagement.
Market Pulse Summary
This announcement highlights Ingersoll Rand’s planned participation in the 44th J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. Pacific Time, featuring its CEO, CFO, and a senior life science executive. It continues a pattern of active investor outreach alongside prior conferences, acquisitions, and board changes. Investors may focus on how management frames its life science technologies, capital allocation, and strategic priorities during the webcast and subsequent replay.
Key Terms
webcast technical
nyse financial
AI-generated analysis. Not financial advice.
DAVIDSON, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Ingersoll Rand Inc. (NYSE: IR), a global provider of mission-critical flow creation and life science and industrial solutions, announced that Vicente Reynal, chairman and chief executive officer, Vik Kini, chief financial officer, and Scott Watson, senior vice president and general manager, Life Science Technologies, will present at the 2026 J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 a.m. Pacific Time.
A real-time audio webcast of the fireside chat can be accessed via the Events and Presentations section of the Ingersoll Rand Investor Relations website here. A replay of the webcast will be available after the conclusion of the fireside chat and can be accessed on the Ingersoll Rand Investor Relations website.
About Ingersoll Rand Inc.
Ingersoll Rand Inc. (NYSE: IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to Making Life Better for our employees, customers, shareholders, and planet. Customers lean on us for exceptional performance and durability in mission-critical flow creation and life science and industrial solutions. Supported by over 80+ respected brands, our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity, and efficiency. For more information, visit IRCO.com.
Contacts:
Investor Relations:
Matthew.Fort@irco.com
Media:
Sara.Hassell@irco.com